







Table 1

	Prospective vs. IPM	Source Pathology	Prim vs Met	ER/HER2	MSK-IMPACT	WGS	RNAseq (Bulk)	Digital Pathology	IF E-cad/p120	WES	RNAseq (bulk)	scRNAseq	scATACseq	MSK-IMPACT
LIO-030	IPM	ILC	Primary	+/-	✓	✓	na(F)	✓	-cyto	✓	✓	✓	✓	✓
LIO-046	IPM	ILC	Primary	+/-	✓	✓	na(F)	✓	-cyto	✓	✓	✓	✓	✓
LIO-053	IPM	ILC	Met (bone)	+/-	na	na	na	✓	-cyto	✓	✓	✓	✓	✓
LIO-055	IPM	ILC	Met (bone)	+/-	na	na	na	✓	-cyto	✓	✓	✓	✓	✓
LIO-086	IPM	ILC	Met (bone)	+/-	na	na	na	✓	-cyto	✓	✓	✓	✓	✓
LIO-153	IPM	ILC	Primary	+/-	na(F)	✓	na(F)	✓	-cyto	✓	✓	✓	✓	✓
LIO-223	IPM	ILC	Met (LN)	+/-	✓	✓	na	✓	-cyto	✓	✓	✓	✓	✓
LIO-268	Prospective	ILC	Met (LN)	+/-	✓	✓	✓	✓	-cyto	✓	✓	✓	✓	✓

IF (E-cad/p120): - negative; +, positive; cyto, cytoplasmic; mem, membranous. na, not available, na(F), sequencing failed.















Table 2

PDX Model	Tumor markers (PDX)	Selection Criteria	E-cadherin IHC (PDX)	p120 IHC (PDX)	Histopathology Evaluation
CTG-2432	ER+/PR+/HER2- Truncating CDH1 Mutation (p.V460Yfs*21)	Negative	Negative	Cytoplasmic	Lobular
CTG-2611	ER+/PR+/HER2- Low CDH1 mRNA	Negative/aberrant (lobular pattern)	Negative	Cytoplasmic	Lobular
CTG-2810	ER+/PR-/HER2- Truncating CDH1 Mutation (p.Q23*)	Weak membranous	Negative	Cytoplasmic	Lobular
CTG-2849	ER+/PR-/HER2- Low CDH1 mRNA	Negative	Negative	Cytoplasmic	Lobular
CTG-2930	ER+/PR+/HER2- Truncating CDH1 Mutation (p.T748Pfs*22)	Negative	Negative	Cytoplasmic	Lobular
CTG-3283	ER+/PR-/HER2- Truncating CDH1 Mutation (p.E494Kfs*28)	Negative	Negative	Cytoplasmic	Lobular
CTG-3399	TNBC	NST	Membranous	Membranous	Ductal
CTG-1714	TNBC	NST	Membranous	Membranous	Ductal
CTG-2518	TNBC	NST	Membranous	Membranous	Ductal
CTG-3434	ER+/PR-/HER2- Low CDH1 mRNA	70% negative, 30% membranous	70% negative, 30% membranous	Mixed cytoplasmic	Mixed NST-ILC